Wall Street analysts expect Marrone Bio Innovations Inc (NASDAQ:MBII) to report $9.01 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Marrone Bio Innovations’ earnings. The lowest sales estimate is $7.92 million and the highest is $10.10 million. Marrone Bio Innovations reported sales of $5.75 million during the same quarter last year, which indicates a positive year-over-year growth rate of 56.7%. The firm is expected to issue its next earnings results on Tuesday, August 13th.
According to Zacks, analysts expect that Marrone Bio Innovations will report full year sales of $31.66 million for the current year, with estimates ranging from $27.00 million to $36.52 million. For the next financial year, analysts anticipate that the company will report sales of $40.70 million, with estimates ranging from $34.00 million to $46.77 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Marrone Bio Innovations.
Marrone Bio Innovations (NASDAQ:MBII) last posted its quarterly earnings data on Thursday, May 9th. The basic materials company reported ($0.04) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.04). Marrone Bio Innovations had a negative return on equity of 123.95% and a negative net margin of 82.82%. The company had revenue of $8.72 million during the quarter, compared to analysts’ expectations of $6.18 million.
Separately, National Securities reissued a “buy” rating and issued a $2.50 price target on shares of Marrone Bio Innovations in a report on Friday, March 15th.
Marrone Bio Innovations stock traded up $0.03 during mid-day trading on Friday, reaching $1.43. 65,029 shares of the company were exchanged, compared to its average volume of 124,295. Marrone Bio Innovations has a twelve month low of $1.10 and a twelve month high of $2.18. The stock has a 50-day moving average price of $1.58. The company has a current ratio of 1.94, a quick ratio of 1.47 and a debt-to-equity ratio of 2.47. The stock has a market capitalization of $158.34 million, a price-to-earnings ratio of -6.81 and a beta of -0.05.
Institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. lifted its holdings in shares of Marrone Bio Innovations by 0.5% in the 4th quarter. BlackRock Inc. now owns 2,800,519 shares of the basic materials company’s stock valued at $4,117,000 after buying an additional 14,014 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Marrone Bio Innovations by 13.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,554,605 shares of the basic materials company’s stock valued at $4,675,000 after buying an additional 303,201 shares during the period. Spark Investment Management LLC lifted its holdings in shares of Marrone Bio Innovations by 47.5% in the 1st quarter. Spark Investment Management LLC now owns 95,000 shares of the basic materials company’s stock valued at $145,000 after buying an additional 30,600 shares during the period. Rhumbline Advisers lifted its holdings in shares of Marrone Bio Innovations by 44.3% in the 4th quarter. Rhumbline Advisers now owns 68,021 shares of the basic materials company’s stock valued at $100,000 after buying an additional 20,882 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in shares of Marrone Bio Innovations in the 1st quarter valued at approximately $74,000. 42.04% of the stock is owned by institutional investors and hedge funds.
About Marrone Bio Innovations
Marrone Bio Innovations, Inc provides bio-based pest management and plant health products primarily for agricultural and water markets in the United States and internationally. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation.
Featured Article: Risk Tolerance
Get a free copy of the Zacks research report on Marrone Bio Innovations (MBII)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Marrone Bio Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations and related companies with MarketBeat.com's FREE daily email newsletter.